AptaTargets
A clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD34—51m (Dealroom.co estimates Oct 2020.)
Company register number B87154118
Madrid Community of Madrid (HQ)
- hard tech
- biotechnology
- horizon europe
- woman founder
- biotech and pharma
- eit ecosystem
- neurology
- eit health
- eit supernovas
- eicfund
- headstart (eit health)
- immune system
- european health catapult (eit health)
- microbiology
- headstart 2018 (eit health)
- rna
- bridgehead europe (eit health)
- european health catapult 2018 (eit health)
- bridgehead europe 2019 (eit health)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.2m | 1.9m | 1.9m | 1.6m | 1.8m | 2.2m | 2.4m |
| % growth | 204 % | 57 % | 2 % | (14 %) | 12 % | 20 % | 8 % |
| EBITDA | <1m | <1m | <1m | <1m | <1m | - | - |
| % EBITDA margin | 2 % | 13 % | 5 % | 13 % | 15 % | - | - |
| Profit | (<1m) | <1m | (<1m) | <1m | <1m | - | - |
| % profit margin | - | 6 % | (2 %) | 2 % | 1 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
* | €2.7m | Early VC | |
N/A | Grant | ||
€40.0k | Grant | ||
€30.0k | Grant | ||
€5.0m | Early VC | ||
* | €2.5m | Grant | |
* | N/A | Early VC | |
| Total Funding | AUD17.5m | ||
Related Content
Recent News about AptaTargets
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.